내분비 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Endocrine Testing Market size is expected to reach USD 8.01 Billion in 2034 from USD 3.89 Billion (2025) growing at a CAGR of 8.36% during 2026-2034.

The Global Endocrine Testing Market is growing steadily due to the rising prevalence of hormonal disorders such as diabetes, thyroid dysfunction, and adrenal imbalances. Increasing awareness about early disease detection and preventive healthcare is encouraging routine endocrine assessments. Expanding geriatric populations and lifestyle-related health conditions are also contributing to greater demand for diagnostic testing services worldwide.

Major growth drivers include technological advancements in immunoassays and automated diagnostic analyzers that provide accurate and rapid results. Growing adoption of point-of-care testing solutions and improved laboratory infrastructure in emerging markets are further fueling expansion. Additionally, rising healthcare expenditure and government initiatives focused on chronic disease management are supporting market development.

Future prospects appear promising as personalized medicine gains traction and hormone-based therapies expand. Integration of digital health platforms and AI-powered diagnostics may enhance test accuracy and efficiency. Increasing investments in research and diagnostic innovation are expected to drive further advancements. As awareness about endocrine health continues to rise, sustained market growth is anticipated globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Human Chorionic Gonadotropin (HCG) Hormone Test
• Thyroid Stimulating Hormone (TSH) Test
• Insulin Test
• Progesterone Test
• Luteinizing Hormone (LH) Test
• Prolactin Test
• Other Test Types

By Technology

• Immunoassay
• Mass Spectroscopy
• Chromatography
• Nucleic Acid Based
• Other Technologies

By End Use

• Clinical Laboratories
• Hospitals
• Diagnostic Centers
• Other End Users

COMPANIES PROFILED

• Abbott, Agilent, Beckman Coulter, Bio RAD, Biomedical Technologies, Biomerieux, DH Tech, Diasorin, Labcorp, Quidelortho, Qiagen, Quest Diagnostics, Roche
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ENDOCRINE TESTING MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Human Chorionic Gonadotropin (HCG) Hormone Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Thyroid Stimulating Hormone (TSH) Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Insulin Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Progesterone Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Luteinizing Hormone (LH) Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Prolactin Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Test Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ENDOCRINE TESTING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. Immunoassay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Mass Spectroscopy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Chromatography Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Nucleic Acid Based Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ENDOCRINE TESTING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Clinical Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ENDOCRINE TESTING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Technology
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Technology
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Technology
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Technology
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Technology
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ENDOCRINE TESTING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott
  • 9.2.2 Agilent
  • 9.2.3 Beckman Coulter
  • 9.2.4 Bio RAD
  • 9.2.5 Biomedical Technologies
  • 9.2.6 Biomerieux
  • 9.2.7 DH Tech
  • 9.2.8 Diasorin
  • 9.2.9 Labcorp
  • 9.2.10 Quidelortho
  • 9.2.11 Qiagen
  • 9.2.12 Quest Diagnostics
  • 9.2.13 Roche